Gastroesophageal Junction Adenocarcinoma Therapeutics Global Market Report 2025
상품코드:1826927
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
위식도 접합부 선암 치료 시장 규모는 최근 급속히 확대되고 있습니다. 2024년 38억 5,000만 달러에서 2025년에는 44억 7,000만 달러에 달하고, CAGR 16.1%를 나타낼 전망입니다. 실적기간의 성장은 헬리코박터 파일로리 감염의 유병률 증가, 바렛 식도의 증례 수 증가, 스크리닝 프로그램 증가, R&D 투자 증가, 헬스케어 접근성 증가로 인한 것입니다.
위식도 접합부 선암 치료 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 16.0%를 나타내 80억 7,000만 달러로 성장할 전망입니다. 예측 기간의 성장은 정밀 종양학에 대한 주목, 집학적 치료 접근법 증가, 액체 생검 사용 증가, 낮은 침습 절차로의 이동, 면역 종양학 치료의 수용 및 사용 증가로 인한 것으로 예측됩니다. 예측 기간의 주요 동향으로는 임상에서 차세대 시퀀서 개발, 표적 방사선 요법의 혁신, 분자 이미징의 진보, 치료 계획의 인공지능 통합, 수술 절차의 진보 등이 있습니다.
위식도 접합부 선암은 식도와 위의 접합부에 생기는 악성 종양으로, 만성적인 산의 역류와 비만, 기타 위험 인자와 관련되는 경우가 많습니다. 그 치료법은 종양의 진행을 지연시키고, 생존율을 향상시키고, 환자의 예후를 개선하도록 설계된 표적요법, 면역요법, 화학요법, 수술 등을 포함합니다.
위식도 접합부 선암의 주요 치료제로는 트라스투주맙과 람실맙이 있습니다. 트라스투주맙은 HER2 양성 위식도 접합부 선암의 치료에 사용되는 표적 치료제로, 암의 증식에 기여하는 HER2 단백질을 저해합니다. 진단은 내시경 검사, X선 검사, 컴퓨터 단층촬영(CT) 검사, 양전자 방사선 단층촬영(PET) 검사 등의 절차에 의해 수행됩니다. 치료 접근법은 식도 절제 수술, 식도 확장술, 화학요법, 표적 치료 등을 포함합니다. 이러한 치료제는 병원 약국, 소매 약국 및 온라인 약국을 통해 판매됩니다.
2025년 봄 미국 관세의 급상승과 이에 따른 무역 마찰은 의료 분야, 특히 필수적인 의료기기, 진단 장비 및 의약품 공급에 큰 영향을 미쳤습니다. 병원과 건강 관리 제공업체는 수입되는 수술 기구, 영상 진단 시스템, 주사기 및 카테터와 같은 소모품의 비용 상승에 시달리고 있으며, 그 대부분은 국내 대체품이 제한되어 있습니다. 이러한 비용 상승이 의료 예산을 압박하기 때문에 일부 의료기관은 장비 업그레이드를 늦추거나 비용 증가를 환자에게 전가하고 있습니다. 게다가 원료와 부품에 대한 관세는 중요한 의약품과 의료기기의 제조에 지장을 주고 공급망의 지연으로 이어지고 있습니다. 이에 비해 업계는 다양한 조달 전략을 채택하고 가능한 한 현지 생산을 확대하고 중요한 의료 제품의 관세 면제를 수행하고 있습니다.
이 조사 보고서는 위식도 접합부 선암 치료 업계 세계 시장 규모, 지역 점유율, 위식도 접합부 선암 치료 시장 점유율을 가진 경쟁업체, 상세한 위식도 접합부 선암 치료 시장 부문, 시장 동향, 비즈니스 기회 등 위식도 접합부 선암 치료 시장 통계를 제공하는 The Business Research Company의 신간 보고서 시리즈 이 위식도 접합부 선암 치료 시장 조사 보고서는 업계의 현재와 미래 시나리오를 자세히 분석하고 필요한 모든 것에 대한 완전한 전망을 제공합니다.
향후 5년간의 성장률 16.0%라고 하는 예측은 전회 예측으로부터 0.2%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세장벽에 의해 스위스나 독일에서 조달되는 면역체크포인트 억제제나 HER2를 표적으로 한 치료제의 비용이 상승하고, 이 침공성 암에 대한 연명치료가 지연되고 종양과의 경비가 상승할 것으로 예측됩니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.
비만률의 상승은 위식도 접합부 선암 치료 시장 성장을 가속할 것으로 예측됩니다. 체지방의 과잉 축적을 특징으로 하는 비만증은 식생활의 혼란, 앉기 쉬운 라이프 스타일, 운동 부족, 가공 식품이나 고칼로리 식품의 섭취 등의 요인에 의해 증가하고 있습니다. GEJA 치료제는 염증, 신진 대사 교란, 호르몬 균형 교란 등 체중 증가를 일으키는 근본적인 메커니즘을 다루는 데 중요한 역할을 합니다. 예를 들어, 2024년 3월, 스위스에 본부를 두고 있는 정부간 기관인 세계보건기구(WHO)는 세계의 약 8명 중 1명이 비만으로 고민하고 있다고 보고했습니다. 이 중에는 과체중으로 분류되는 성인이 25억명 포함되어 있으며, 그중 8억 9,000만명이 비만과 공존하고 있습니다. 성인 중 43%가 과체중이고 16%가 비만으로 분류됩니다. 또한 5세 미만의 과체중 어린이의 수는 3,700만 명에 달했습니다. 따라서 비만율 증가는 위식도 접합부 선암 치료 시장 확대에 박차를 가하고 있습니다.
위식도 접합부 선암 치료 시장 주요 기업은 치료 효과를 높이고 환자 결과를 개선하며 기존 치료에 대한 내성을 다루는 혁신적인 병용 요법의 개발에 주력하고 있습니다. 병용 요법은 약물 및 치료법과 같은 2종 이상의 치료제를 사용하여 효능을 향상시키고 질병의 여러 측면을 동시에 표적화하는 것입니다. 예를 들어 2024년 10월 일본 제약회사인 아스테라스 제약은 플루오로피리미딘 및 백금 제제를 포함한 화학요법과 병용하는 졸베툭시맙-clzb의 미국 식품의약국(FDA)의 승인을 받았습니다. 졸베툭시맙-clzb는 위암과 GEJ 암으로 고발현하는 클로딘 18.2를 특이적으로 표적으로 하는 퍼스트 인 클래스의 단일클론 항체이며, 치료 정밀도와 치료 효과를 향상시킵니다. CLDN18.2를 발현하고 있는 암세포에 선택적으로 결합하는 것으로, 치료 효과를 최적화하면서, 건강 조직에의 데미지를 최소한으로 억제하는 표적 접근이 가능해집니다.
2023년 1월 미국의 생명공학 기업인 Leap Therapeutics Inc.는 Flame Biosciences Inc.를 1억 1,500만 달러로 인수했습니다. 이 인수를 통해 Leap Therapeutics는 Flame Biosciences가 개발한 혁신적인 암 치료제를 통합하고, 표적 치료제의 포트폴리오를 확대하고, GEJA 및 기타 암에 대한 최첨단 솔루션을 개발하기 위한 연구 개발을 진행함으로써 암 영역의 파이프라인을 강화합니다. 미국에 본사를 둔 Flame Biosciences Inc.는 위식도 접합부 선암의 치료제 개발에 특화되어 있으며 Leap Therapeutics의 동시장에서의 능력은 더욱 강화됩니다.
위식도 접합부 선암 치료 시장에는 방사선 요법, 면역 요법, 외과 종양학, 완화 케어 등의 서비스와 혈관신생 억제제, 화학 방사선 요법, 바이오시밀러, 병용 요법 등 관련 제품을 제공하는 기업이 얻는 수익이 포함됩니다. 시장 가치에는 서비스 제공업체가 판매하거나 서비스 제공 내에 포함된 관련 상품의 가치가 포함됩니다. 기업간에 거래되거나 최종 소비자에게 판매되는 재화 및 서비스만 포함됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 위식도 접합부 선암 치료 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 위식도 접합부 선암 치료 시장 : 성장률 분석
세계의 위식도 접합부 선암 치료 시장 실적 : 규모와 성장(2019-2024년)
세계의 위식도 접합부 선암 치료 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 위식도 접합부 선암 치료 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 위식도 접합부 선암 치료 시장 : 약물별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
트라스투주맙
라무시루맙
세계의 위식도 접합부 선암 치료 시장 : 진단별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
내시경
X선
컴퓨터 단층 촬영(CT) 스캔
양전자 방출 단층 촬영(PET) 스캔
세계의 위식도 접합부 선암 치료 시장 : 치료별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
식도 절제술
식도 확장술
항암 치료
표적 치료
세계의 위식도 접합부 선암 치료 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
온라인 약국
세계의 위식도 접합부 선암 치료 시장 : 트라스투주맙 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
단일 요법
항암제 병용 요법
세계의 위식도 접합부 선암 치료 시장 : 라무시루맙 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
단일 요법
파클리탁셀 병용 요법
제7장 지역별/국가별 분석
세계의 위식도 접합부 선암 치료 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 위식도 접합부 선암 치료 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
위식도 접합부 선암 치료 시장 : 경쟁 구도
위식도 접합부 선암 치료 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
F Hoffmann-La Roche AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bristol-Myers Squibb Company : 개요, 제품 및 서비스, 전략 및 재무 분석
AstraZeneca plc : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Teva Pharmaceutical Industries Ltd.
Daiichi Sankyo Company Limited
Genentech Inc.
Incyte Corporation
Ono Pharmaceutical Co. Ltd.
BeiGene Ltd.
Zymeworks Inc.
Zai Lab Limited
ImmunoGen Inc.
Elevar Therapeutics Inc.
Mirati Therapeutics Inc.
Shanghai Henlius Biotech Inc.
Taiho Pharmaceutical Co. Ltd.
LintonPharm Ltd.
Celltrion Healthcare Co. Ltd.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
위식도 접합부 선암 치료 시장(2029년) : 새로운 기회를 제공하는 국가
위식도 접합부 선암 치료 시장(2029년) : 새로운 기회를 제공하는 부문
위식도 접합부 선암 치료 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
KTH
영문 목차
영문목차
Gastroesophageal junction adenocarcinoma is a malignant tumor that forms at the junction of the esophagus and stomach, often linked to chronic acid reflux, obesity, and other risk factors. Its treatment options include targeted therapies, immunotherapy, chemotherapy, and surgical procedures designed to slow tumor progression, improve survival rates, and enhance patient outcomes.
The primary therapeutics for gastroesophageal junction adenocarcinoma include trastuzumab and ramucirumab. Trastuzumab is a targeted therapy drug used to treat HER2-positive gastroesophageal junction adenocarcinoma by blocking the HER2 protein, which contributes to cancer growth. Diagnosis is conducted through procedures such as endoscopy, X-ray, computed tomography (CT) scan, and positron emission tomography (PET) scan. Treatment approaches include esophagectomy surgery, esophageal dilation, chemotherapy, and targeted therapy. These therapeutics are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The gastroesophageal junction adenocarcinoma therapeutics market research report is one of a series of new reports from The Business Research Company that provides gastroesophageal junction adenocarcinoma therapeutics market statistics, including the gastroesophageal junction adenocarcinoma therapeutics industry global market size, regional shares, competitors with the gastroesophageal junction adenocarcinoma therapeutics market share, detailed gastroesophageal junction adenocarcinoma therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the gastroesophageal junction adenocarcinoma therapeutics industry. This gastroesophageal junction adenocarcinoma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The gastroesophageal junction adenocarcinoma therapeutics market size has grown rapidly in recent years. It will grow from $3.85 billion in 2024 to $4.47 billion in 2025 at a compound annual growth rate (CAGR) of 16.1%. The growth in the historic period can be attributed to the increasing prevalence of helicobacter pylori infection, the increasing number of barrett's esophagus cases, the growing number of screening programs, the increasing research and development investment, and the rise in healthcare access.
The gastroesophageal junction adenocarcinoma therapeutics market size is expected to see rapid growth in the next few years. It will grow to $8.07 billion in 2029 at a compound annual growth rate (CAGR) of 16.0%. The growth in the forecast period can be attributed to a focus on precision oncology, a rise in multidisciplinary treatment approaches, a growing use of liquid biopsies, a shift toward minimally invasive procedures, and an increasing acceptance and use of immuno-oncology treatments. Major trends in the forecast period include the development of next-generation sequencing in clinical practice, innovations in targeted radiation therapy, advancements in molecular imaging, the integration of artificial intelligence in treatment planning, and advancements in surgical techniques.
The forecast of 16.0% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to increase costs for immune checkpoint inhibitors and HER2-targeted therapies sourced from Switzerland and Germany, delaying life-extending treatments for this aggressive cancer and raising oncology department expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising obesity rates are expected to drive the growth of the gastroesophageal junction adenocarcinoma (GEJA) therapeutics market. Obesity, a condition characterized by excessive body fat accumulation, is increasing due to factors such as poor dietary habits, sedentary lifestyles, lack of physical activity, and the consumption of processed and high-calorie foods. GEJA therapeutics play a crucial role in addressing the underlying mechanisms that contribute to weight gain, including inflammation, metabolic disruption, and hormonal imbalances, which can be exacerbated by the disease. For instance, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that approximately one in eight people worldwide were struggling with obesity. This included 2.5 billion adults classified as overweight, with 890 million of them living with obesity. Among adults, 43% were overweight, and 16% were classified as obese. Additionally, the number of overweight children under the age of 5 reached 37 million. Therefore, the growing obesity rates are fueling the expansion of the GEJA therapeutics market.
Leading companies in the GEJA therapeutics market are focused on developing innovative combination therapies to enhance treatment efficacy, improve patient outcomes, and address resistance to existing treatments. Combination therapy involves using two or more therapeutic agents, such as drugs or treatment modalities, to improve effectiveness and target multiple aspects of a disease simultaneously. For example, in October 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for zolbetuximab-clzb in combination with fluoropyrimidine- and platinum-containing chemotherapy. Zolbetuximab-clzb is a first-in-class monoclonal antibody specifically targeting Claudin 18.2, a protein highly expressed in gastric and GEJ cancers, thereby improving treatment precision and effectiveness. By selectively binding to CLDN18.2-expressing cancer cells, this therapy enables a targeted approach, minimizing damage to healthy tissues while optimizing therapeutic outcomes.
In January 2023, Leap Therapeutics Inc., a US-based biotech company, acquired Flame Biosciences Inc. for $115 million. This acquisition strengthens Leap Therapeutics' oncology pipeline by integrating innovative cancer therapies developed by Flame Biosciences, expanding its portfolio of targeted treatments, and advancing research efforts to develop cutting-edge solutions for GEJA and other cancers. Flame Biosciences Inc., a US-based company, specializes in developing therapeutics for gastroesophageal junction adenocarcinoma, further enhancing Leap Therapeutics' capabilities in this market.
Major players in the gastroesophageal junction adenocarcinoma therapeutics market are Pfizer Inc., F Hoffmann-La Roche AG, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Genentech Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., Zymeworks Inc., Zai Lab Limited, ImmunoGen Inc., Elevar Therapeutics Inc., Mirati Therapeutics Inc., Shanghai Henlius Biotech Inc., Taiho Pharmaceutical Co. Ltd., LintonPharm Ltd., Celltrion Healthcare Co. Ltd.
North America was the largest region in the gastroesophageal junction adenocarcinoma therapeutics market in 2024. The regions covered in gastroesophageal junction adenocarcinoma therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the gastroesophageal junction adenocarcinoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The gastroesophageal junction adenocarcinoma therapeutics market includes revenues earned by entities by providing services such as radiation therapy, immunotherapy, surgical oncology, and palliative care and related products such as angiogenesis inhibitors, chemoradiation therapy, biosimilars, and combination therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Gastroesophageal Junction Adenocarcinoma Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on gastroesophageal junction adenocarcinoma therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for gastroesophageal junction adenocarcinoma therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gastroesophageal junction adenocarcinoma therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug: Trastuzumab; Ramucirumab
3. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Trends And Strategies
4. Gastroesophageal Junction Adenocarcinoma Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Growth Analysis And Strategic Analysis Framework
5.1. Global Gastroesophageal Junction Adenocarcinoma Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Growth Rate Analysis
5.4. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Total Addressable Market (TAM)
6.1. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Trastuzumab
Ramucirumab
6.2. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Endoscopy
X-ray
Computed Tomography (CT) Scan
Positron Emission Tomography (PET) Scan
6.3. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Esophagectomy Surgery
Esophageal Dilation
Chemotherapy
Targeted Therapy
6.4. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
6.5. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Sub-Segmentation Of Trastuzumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monotherapy
Combination Therapy With Chemotherapy
6.6. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Sub-Segmentation Of Ramucirumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monotherapy
Combination Therapy With Paclitaxel
7. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Regional And Country Analysis
7.1. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Gastroesophageal Junction Adenocarcinoma Therapeutics Market
9.1. China Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
9.2. China Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Gastroesophageal Junction Adenocarcinoma Therapeutics Market
10.1. India Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Gastroesophageal Junction Adenocarcinoma Therapeutics Market
11.1. Japan Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
11.2. Japan Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Gastroesophageal Junction Adenocarcinoma Therapeutics Market
12.1. Australia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Gastroesophageal Junction Adenocarcinoma Therapeutics Market
13.1. Indonesia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Gastroesophageal Junction Adenocarcinoma Therapeutics Market
14.1. South Korea Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
14.2. South Korea Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market
15.1. Western Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
15.2. Western Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Gastroesophageal Junction Adenocarcinoma Therapeutics Market
16.1. UK Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.1. Spain Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market
21.1. Eastern Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
21.2. Eastern Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Gastroesophageal Junction Adenocarcinoma Therapeutics Market
22.1. Russia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market
23.1. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
23.2. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Gastroesophageal Junction Adenocarcinoma Therapeutics Market
24.1. USA Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
24.2. USA Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Gastroesophageal Junction Adenocarcinoma Therapeutics Market
26.1. South America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
26.2. South America Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Gastroesophageal Junction Adenocarcinoma Therapeutics Market
27.1. Brazil Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Gastroesophageal Junction Adenocarcinoma Therapeutics Market
28.1. Middle East Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
28.2. Middle East Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market
29.1. Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Overview
29.2. Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Gastroesophageal Junction Adenocarcinoma Therapeutics Market Competitive Landscape And Company Profiles
